Literature DB >> 12943679

Identification of secreted CD155 isoforms.

Béatrice Baury1, Damien Masson, Brian M McDermott, Anne Jarry, Hervé M Blottière, Philippe Blanchardie, Christian L Laboisse, Patrick Lustenberger, Vincent R Racaniello, Marc G Denis.   

Abstract

The CD155 gene is a member of the immunoglobulin superfamily. We first demonstrate the existence of soluble CD155 (sCD155) isoforms in culture medium conditioned by CD155-expressing cells, in human serum and in cerebrospinal fluid. sCD155 concentration was measured in human serum and cerebrospinal fluid using a specific ELISA. Analysis of conditioned media indicated that sCD155 release does not require protease activity. In order to determine which tissues are responsible for sCD155 expression, we have quantified CD155 mRNAs in human normal tissues. The highest expression was observed in liver. The CD155alpha transcript is the most abundant and the proportion of the CD155beta and CD155gamma variants was similar between the tissues. Finally, serum purified sCD155 reduces poliovirus entry mediated by membrane-bound CD155. The high level of CD155 synthesis in many tissues and the presence of sCD155 in biological fluids suggest the existence of an important role for the protein in cellular function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943679     DOI: 10.1016/s0006-291x(03)01560-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  Identification of leucocyte surface protein interactions by high-throughput screening with multivalent reagents.

Authors:  Lei Jiang; A Neil Barclay
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

2.  Polio, still lurking in the shadows.

Authors:  Anthony N van den Pol
Journal:  J Neurosci       Date:  2013-01-16       Impact factor: 6.167

Review 3.  Poliovirus Receptor: More than a simple viral receptor.

Authors:  Jonathan R Bowers; James M Readler; Priyanka Sharma; Katherine J D A Excoffon
Journal:  Virus Res       Date:  2017-09-08       Impact factor: 3.303

Review 4.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

5.  Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice.

Authors:  Tsukasa Nabekura; Kazuko Shibuya; Eri Takenaka; Hirayasu Kai; Kai Shibata; Yumi Yamashita; Kyoichi Harada; Satoko Tahara-Hanaoka; Shin-ichiro Honda; Akira Shibuya
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

Review 6.  Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus.

Authors:  Julie K Pfeiffer
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

Review 7.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

8.  Establishment of an enzyme-linked immunosorbent assay system for determining soluble CD96 and its application in the measurement of sCD96 in patients with viral hepatitis B and hepatic cirrhosis.

Authors:  J Gong; C Zhu; R Zhuang; C Song; Q Li; Z Xu; Y Wei; K Yang; A Yang; L Chen; B Jin
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

9.  Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients.

Authors:  Zhuwei Xu; Tao Zhang; Ran Zhuang; Yun Zhang; Wei Jia; Chaojun Song; Kun Yang; Angang Yang; Boquan Jin
Journal:  BMC Immunol       Date:  2009-06-02       Impact factor: 3.615

10.  Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma.

Authors:  Mohamed Osman Azzazi; Hany Mohamed Hegab; Amro Mohamed Sedky El-Ghammaz; Heba Mohamed Saber; Youssef Adel Afifi
Journal:  Clin Exp Med       Date:  2021-07-03       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.